News – Page 868 – Endpoints News

Stanley and Rosanne Crooke stay focused on anti-sense, stealing back patients from disease with N-of-1 tech

6 years ago

Xencor, Verastem ink new deals; Scynexis' lead drug scores again

6 years ago

Steepest decline in US cancer mortality ever recorded, study finds

6 years ago

Just how big is the biopharma dealmaking world? In 2019 we saw megabillions in cash change hands, and that's just the ...

6 years ago

Mark Alles begins his post-Celgene career on the board of a US-China biotech led by a former colleague

6 years ago

How pancreatic RAS tumors protect themselves. Researchers point to a new protein — and maybe a new treatment

6 years ago

WuXi-backed Adagene scores $69M round led by General Atlantic to push antibodies where Bristol-Myers struggled

6 years ago

Aim for the brain: RA Capital bets on Colorado biotech to reformulate epilepsy drug for refractory patients

6 years ago

A for augmented: Cambridge AI company out to capture biomedical knowledge gets $60M from Mayo, Silicon Valley VC

6 years ago

Fish oil pill for NASH? Dutch biotech scores $40M injection to make a mark in the bustling field

6 years ago

'Burner' phones and Ariad secrets: Goldman Sachs banker pleads guilty for his role in global insider trading ring

6 years ago

Thomas Lynch finds a new home as leader of the Fred Hutch — and he’s staying focused on cancer breakthroughs

6 years ago

Rhythm CEO Keith Gottesdiener hits the exit; Takeda sets up an AI discovery program at MIT

6 years ago

Vascepa sparkle set to light up Amarin's fourth quarter revenue

6 years ago

AstraZeneca gets in on RNA game with MiNA research collaboration

6 years ago

SpaceX investor backs Toronto AI upstart's journey into the 'dark region' of genetic diseases

6 years ago

Apellis soars as Alexion rival outshines blockbuster standard bearer Soliris — then fresh doubts scuttle spike

6 years ago

MPM backs new biotech in the hunt for non-opioid painkiller

6 years ago

Fresh from $94.5M crossover round, Frazier-groomed dermatology biotech shoots for $100M IPO

6 years ago

A Bay Area biotech spells out the stock package it used to woo a new CEO from Big Pharma

6 years ago

As investors soured on his bets, records show Woodford paid himself handsome dividends

6 years ago

Fresh from a Pfizer buyout, Luca Santarelli’s crew has created a new company — banking new funds and steering ...

6 years ago

Merck's PD-1 star Keytruda flunks a key survival endpoint in SCLC — cue the unfavorable Tecentriq comparisons

6 years ago

'U snooze u lose': Judgment day for $100M biotech insider trading scheme looms as son of former Ariad director stands ...

6 years ago

First page Previous page 865 866 867868869 870 871 Next page Last page